久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Luye Pharma’s Shares Drop on Acquisition of Two Biological Antibodies

firstwordpharmaDecember 25, 2018

Tag: clinical development , monoclonal antibody , LUYE PHARMA , clinical development

Luye Pharma announced that it acquired the biological monoclonal antibodies, LY01011 and LY09004, from Shandong Boan Biological Technology for nearly $73 million, reported Investing.com.

 

Both drugs are in clinical development and are expected to launch in 2023, if approved.

 

Shandong Luye will pay 60 percent of the agreed amount five days after signing the agreement, and another 20 percent five days after Boan completes the Phase III trial of the compounds.

 

The remaining 20 percent will be due five days after China's National Medical Products Administration clears the products.

Previous:Nature publication reports first-in-human trial of a novel actively personalized therapeutic vaccine for brain cancer

Next:FDA clears Zydus Cadila to market generic versions of Mayne Pharma's Doryx, Takeda's Uloric

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service